Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 6/20 | 0.45 |
| ▸ | GPR35 | Q9HC97 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | GSK3B | P49841 | 2/20 | 0.39 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 5/20 | 0.39 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24696501 | 0.80 | DGAT1 (0.42) | ALDH1A1KDM4EMEN1MAPTKMT2A | |
| SCHEMBL17201680 | 0.79 | PTPN2 (0.43) | ALDH1A1KDM4EMEN1MAPTKMT2A | |
| SCHEMBL16610036 | 0.79 | DAO (0.46) | DAOGPR35ALDH1A1KDM4EMEN1 | |
| SCHEMBL899479 | 0.79 | GSK3B (0.61) | DAOGPR35ALDH1A1KDM4EMEN1 | |
| SCHEMBL18701659 | 0.77 | DAO (0.45) | DAOGPR35ALDH1A1KDM4EMEN1 | |
| Hydrochloric Acid SCHEMBL8935203 | 0.77 | GSK3B (0.59) | DAOGPR35ALDH1A1KDM4EMEN1 | |
| Bromide SCHEMBL8935164 | 0.77 | GSK3B (0.59) | DAOGPR35ALDH1A1KDM4EMEN1 | |
| SCHEMBL30020630 | 0.77 | GPR35 (0.48) | DAOGPR35ALDH1A1KDM4EMEN1 | |
| SCHEMBL18701754 | 0.76 | DAO (0.63) | DAOGPR35ALDH1A1KDM4EMEN1 | |
| SCHEMBL28891536 | 0.76 | DAO (0.43) | DAOGPR35ALDH1A1KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240299385-A1 | 3-PYRROLYLSULFONAMIDE COMPOUNDS AS GPR17 ANTAGONISTS | REWIND THERAPEUTICS NV (BE) | 2024-09-12 | — | — | US | disclosed |
| EP-4347558-A1 | 3-PYRROLYLSULFONAMIDE COMPOUNDS AS GPR17 ANTAGONISTS | ReWind Therapeutics NV (BE) | 2024-04-10 | — | — | EP | disclosed |
| CN-117794898-A | 3-pyrrolylsulfonamide compounds as GPR17 antagonists | 瑞文德医疗公众有限公司 | 2024-03-29 | — | — | CN | disclosed |
| WO-2022254027-A1 | 3-PYRROLYLSULFONAMIDE COMPOUNDS AS GPR17 ANTAGONISTS | REWIND THERAPEUTICS NV (BE) | 2022-12-08 | — | — | WO | disclosed |
| WO-2022254027-A1 | 3-PYRROLYLSULFONAMIDE COMPOUNDS AS GPR17 ANTAGONISTS | REWIND THERAPEUTICS NV (BE) | 2022-12-08 | — | — | WO | disclosed |
| US-9725459-B2 | 3-oxo-tetrahydro-furo[3,2-B]pyrrol-4(5H)-yl) derivatives I | GRUNENTHAL GMBH (DE) | 2017-08-08 | — | — | US | disclosed |
| EP-3140309-A1 | 3-OXO-TETRAHYDRO-FURO[3,2-B]PYRROL-4(5H)-YL) DERIVATIVES I | Grünenthal GmbH (DE) | 2017-03-15 | — | — | EP | disclosed |
| WO-2015161928-A1 | 3-OXO-TETRAHYDRO-FURO[3,2-B]PYRROL-4(5H)-YL) DERIVATIVES I | Grünenthal GmbH (DE) | 2015-10-29 | — | — | WO | disclosed |
| US-20150307507-A1 | 3-OXO-TETRAHYDRO-FURO[3,2-B]PYRROL-4(5H)-YL) DERIVATIVES I | Grünenthal GmbH (DE) | 2015-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150307507-A1 | 3-OXO-TETRAHYDRO-FURO[3,2-B]PYRROL-4(5H)-YL) DERIVATIVES I | CTSK, OPRK1, CAT | DAO 741/4885GPR35 1597/4885ALDH1A1 886/4885 |
| US-20240299385-A1 | 3-PYRROLYLSULFONAMIDE COMPOUNDS AS GPR17 ANTAGONISTS | GPR3, GPR27, GPR65 | DAO 4637/4885GPR35 10/4885ALDH1A1 3504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.